**OBJECTIVE**

The objective of this study was to characterise the dynamic response of the INVOS™ system compared to Nonin QUANOX™*, CASMED FORE-SIGHT ELITE™*, and Masimo Root™ O3™ NIRS monitors during an induced hypoxic state in an animal model.

**METHODOLOGY**

Three juvenile Yorkshire cross swine, weighing 14–17 kg, were enrolled in this nonblinded, non-randomised, prospective study. Animals were placed in an induced hypoxic state and data was collected at 15-second intervals. Fourteen to 15 runs were completed on each animal and a total of 44 runs were collected. During each run, one adult sensor from the INVOS™ system and one adult sensor from either CASMED, Nonin, or Masimo system were placed on the cranium simultaneously. Cerebral oxygenation values from both devices and oxygen levels were recorded at the same 15-second intervals. SpO2 levels were measured concurrently and used for comparison. A 20% reduction from baseline was chosen given relevance of this as an intervention threshold from previous work.

**RESULTS**

The mean difference in time to reach 80% of baseline relative to the INVOS™ cerebral oximeter was significantly slower for Masimo and CASMED cerebral oximeters (mean time = +183 seconds, p=0.0002 and +151 seconds, p=0.0008, respectively). The Nonin cerebral oximeter took 25 seconds longer to reach the 80% threshold but was not significantly different from the INVOS™ cerebral oximeter (p=0.6053). The magnitude of response was greater with the INVOS™ system compared to competitors. At ten minutes, the INVOS™ system was 26 percentage points lower than the CASMED system and 21 percentage points lower than the Masimo system (p<.0001 and p=0.0041, respectively). The INVOS™ system was 10 percentage points lower than the Nonin system but was not statistically significant (p=0.304). Finally, when SpO2 values declined to a critical level (45 to 47 percentage points decrease from baseline), the INVOS™ system demonstrated the largest mean reduction (~37% from baseline, followed by the Nonin, CASMED, and Masimo systems at ~30%, ~17%, and ~14%, respectively). Both the INVOS™ system and Nonin system had statistically greater reductions than either the Masimo or CASMED systems (p<0.0001).

**CONCLUSION**

The INVOS™ 5100C cerebral oximeter demonstrated faster times to 80% of baseline, greater magnitude proportional tracking with SpO2, levels over time, and a magnitude more consistent with SpO2, at a specified level than either the Masimo Root™ O3™ system or CASMED FORE-SIGHT ELITE™ cerebral oximeters. While Nonin QUANOX™ system was not found to be statistically different than the INVOS™ system, all the same trends were observed. The acute hypoxia model used in the study demonstrated a difference in performance related to speed of reaction, magnitude of reaction, and correlation to SpO2, in a transition from normal oxygen saturation to a deeply hypoxic state. The INVOS™ monitoring system demonstrated a unique response as compared to the other monitors tested.

The study was designed to assess performance under a clinically relevant scenario and intervention threshold. Previous studies have shown that intervention based on an 80% of baseline threshold has resulted in improved patient outcomes. The 80% threshold was thus used in this study given its proven clinical relevance while monitoring with the INVOS™ system.

Figure 1 demonstrates the speed in which INVOS™ system responded to induced hypoxia. The INVOS™ system reached the 80% threshold first, followed by the Nonin QUANOX™ system (25 seconds later), CASMED FORE-SIGHT ELITE™ cerebral oximeter (151 seconds later), and finally the Masimo Root™ O3™ system, which was the slowest (183 seconds later).

![Figure 1. The INVOS™ system reached 80% threshold faster than the competitors.](image-url)
Figure 2 demonstrates the magnitude of response to hypoxia of the INVOS™ system in relation to the competitors. The INVOS™ system responded 10% lower than the Nonin system, 21% lower than the Masimo system, and 26% lower than the CASMED system. A response that is more proportional to the physiological change may result in interventions appropriate for the change compared to that of a stable shallow response.

The INVOS™ system demonstrated a greater response to hypoxia at 10 minutes

![Graph showing mean depth of response at 10 minutes](image)

<table>
<thead>
<tr>
<th>System</th>
<th>Mean difference from baseline</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonin</td>
<td>10% deeper</td>
<td>ns</td>
</tr>
<tr>
<td>INVOS™ system</td>
<td>21% deeper</td>
<td>.0041</td>
</tr>
<tr>
<td>Masimo</td>
<td>26% deeper</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

Figure 3 demonstrates the correlation between SpO₂ values and mean rSO₂ values. SpO₂ values were decreased to 55%, an extremely hypoxic state. This figure illustrates that when SpO₂ levels reached 55% (a 45% reduction from baseline), the INVOS™ system mean rSO₂ % values decreased 37% from baseline, followed by Nonin system (30% reduction), CASMED system (17% reduction), and Masimo system with the least decrease (14% reduction from baseline).

The INVOS™ system demonstrated a higher % change from baseline when SpO₂ values reduced

![Graph showing % change from baseline](image)

<table>
<thead>
<tr>
<th>System</th>
<th>% change from baseline</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>INVOS™ system</td>
<td>37% change</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Nonin</td>
<td>30% change</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>CASMED</td>
<td>17% change</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Masimo</td>
<td>14% change</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

1. Based on internal study. A non-GLP comparison study of the INVOS™ NIRS system to competitive regional oxygen systems. 2015. as seen in comparative video with ULF Borg performing laboratory procedures.
2 Alma Road, Macquarie Park NSW 2113 Australia Tel: +61 2 9857 9000 Fax: +61 2 9889 5167 Toll Free: 1800 668 670
Medtronic New Zealand Ltd
Level 3 - Building 5, 666 Great South Road, Penrose, Auckland 1051 New Zealand Fax: +64 9 918 3742 Toll Free: 0800 377 807
© Medtronic 2018 All Rights Reserved. PM 374-12-17 ANZ. #4880-052018